


Business update Q1 2024

April 2024







1//

Overview Q1 2024





BUSINESS PERFORMANCE	Positive start of 2024, with revenue growth driven mainly by pharma's strong performance in Spain and international markets.
FINANCIAL POSITION	Double-digit profit growth contributing to an increase in cash generation now that the final phases of the Derio and ISF industrial investments have been reached.
R&D&i	Preparation of bilastine parenteral dossier validation (submission to German Agency BfArM Q3 2024). New studies and publications to expand pediatric use of bilastine. Positive progress in the clinical phases of the 2 mesalazine projects.
ESG	Initiated the Dual Materiality analysis, which provides a two-way approach: knowing how our operations impact the environment (environmental and social), and how these external factors affect our financial performance.




Key figures

Total Income	139,4 M€ +7 %	EBITDA*	41 M€ +10 %
Income top 3 molecules	58,3 M€ +5 %	EBIT**	35,9 M€ +10 %
Total international income	80,4 M€ +6 %	Net profit	30,4 M€ +10%



*Operating profit before depreciation and amortization ** Operating profit






2//

Business update Q1 2024




Solid growth across the entire pharma portfolio

Total income by portfolio line					
M€	Q1 2024	Q1 2023	%		
Pharma	126,5	116,4	9%		
Pharma top 3 molecules	58,3	55,5	5%		
Rest of Pharma	68,2	61,0	12%		
Animal Nutrition and Health	12,9	13,6	-5%		
Total	139,4	130,1	7%		



Data are rounded







Growth driven by Pharma areas, with particularly strong performance in Spain

Total income by business areas


M€	Q1 2024	Q1 2023	%
Pharma	126,5	116,4	9%
Pharma Spain	47,4	41,6	14%
Pharma International (without licences)	44,0	40,2	9%
Pharma Licences	35,1	34,6	1%
Animal Nutrition and Health	12,9	13,6	-5%
Total	139,4	130,1	7%

Total income by geography*

M€	Q1 2024	Q1 2023	%
National	59,0	53,9	9%
International	80,4	76,2	6%
Total	139,4	130,1	7%

Data are rounded

* National: Income pharma Spain + NySA Spain + Licences out Spain International: Subsidiaries + exports + Licences out (outside Spain)





9

Pharma Spain. Strong start of the year in all sales channels



INCOME SPAIN PHARMA			
ſI€	Q1 2024	Q1 2023	%var
Spain Pharma	47,4	41,6	14%
Prescription	30,2	27,5	10%
Bilastine	4,3	4,1	
Calcifediol	11,5	11,3	
Mesalazine	1,7	1,8	
Other Products	12,8	10,4	
Healthcare & Consumer	17,1	14,1	21%

Data are rounded

Highlights Q1 2024

PRESCRIPTION

Good performance in the first quarter. Bilastine offsets price reductions with new ophthalmic and orodispersible formats. The respiratory franchise consolidates (+22%) while calcifediol continues to grow modestly.

HEALTHCARE & CONSUMER

Good evolution of the different products, especially those related to respiratory and digestive pathologies.



Business update Q1 2024

Pharma International (without licenses). Good performance especially in the new MEA project

INCOME INTERNATIONAL (without licenses)



M€	Q1 2024	Q1 2023	%var
International (withour licenses)	44,0	40,2	9%
Subsidiaries LATAM	20,5	20,0	2%
Central American Caribbean	6,7	6,3	
Colombia	4,0	3,8	
Chile	3,7	4,6	
Mexico	3,4	2,7	
Ecuador	2,0	1,7	
Peru	0,7	0,8	
Subsidiaries Europe	11,1	10,5	7%
Portugal	8,9	8,2	
Italy	2,2	2,3	
Middle East-Africa	9,3	6,5	42%
Direct export	7,9	6,0	
Gulf	1,3	0,2	
Nigeria	0,1	0,3	
Export ROW*	3,1	3,2	-3%

Highlights Q1 2024

Faes LATAM

- Good growth in **Mexico and Ecuador** due to the performance of Calcifediol.
- Moderate growth in Central America (Global Farma) and Colombia, where growth returned after the market contraction in 2023. In both cases, the product mix had a positive impact on the margin.
- In **Chile** there was a temporary decline in sales due to the (expected) loss of a product tender.

Faes OMA

- Total sales to the Gulf (Novosci + Faes Export to the area) grew +1m €.
- Sub-Saharan Africa: + €1.2m growth
- Nigeria decreases in € due to Naira devaluation

* Rest of the world

Business update Q1 2024

Licenses. Moderate growth in line with expectations



INCOME LICENSES			
M€	Q1 2024	Q1 2023	%var
Licenses	35,1	34,6	1%
Bilastine	28,6	28,0	2%
Other products	6,5	6,6	-1%

Data are rounded

Highlights Q1 2024

LICENSES BILASTINE

Bilastine licensing performance remains positive, despite the maturity of the product, underpinned by:

- Strong sell out in core markets at the start of 2024, such as Canada (+38%) or Japan.
- Growth in newer markets such as Australia, China and Germany.
- The impulse provided by the new life-cycle products of the molecule.

OTHER LICENSES

- Sales to our customers grew 24% in value terms thanks to the recent launches in new markets of Calcifediol, as well as the success of mesalazine in some countries (Poland and the Nordics) and Citicoline (Italy).
- The total revenue comparison vs. 2023 does not yet show this strong organic growth, given that Q1 2023 includes a significant one-off milestone income.



Business update Q1 2024

Animal nutrition and health. We continue to face challenges in the sector



INCOME FARM FAES					
M€ Q12024 Q12023 %var					
Animal nutrition and health	12,9	13,6	-5%		
Ingaso Farm	6,9	7,9			
Tecnovit	5,4	5,0			
Capselos	0,4	0,4			
LATAM Subsidiaries	0,2	0,3			

Data are rounded

Highlights Q1 2024

- Sales continue to be hampered by the lack of piglets due to emerging diseases, a situation that we hope will improve during the year as a result of the measures adopted by the sector.
- Capselos shows results of the new Feed & Food diversification strategy.
- Construction of the new ISF plant is progressing well.





3//

Results and Outlook



Double-digit profit growth

Thousand €	Q1 2024	Q1 2023	%change
Ordinary income (sales)	131.133	118.450	10,7%
Other operating income	7.892	11.612	-32,0%
work carried out by the company for its assets	406	0	-
Tota Income	139.431	130.062	7,2%
Cost of sales	-42.330	-39.149	8,1%
Gross margin	97.100	90.913	6,8%
Personnel expenses	-27.835	-26.286	5,9%
Other operating expenses	-28.301	-27.469	3,0%
Depreciation and impairment fixed assets	-5.047	-4.610	9,5%
EBIT	35.917	32.548	10,4%
Financial gain/losses	132	28	375,4%
Profit before tax	36.049	32.575	10,7%
Corporate tax	-5.602	-4.897	14,4%
Net Profit	30.447	27.679	10,0%
Profit to the Parent Company	30.465	27.615	10,3%

Highlights Q1 2024

- Margin growth in line with revenues.
- Expenditure growth in Q1 below revenue growth and annual spending expectations.
- Increase in expenses expected in the coming quarters related to increased activity in R&D, production and sales, paired with salary inflation.



In 2024, even with some major challenges on the horizon, we will continue to grow especially driven by our international business expansion

Guidance 2024		 Impacts 2024 Double-digit growth in LATAM & MEA 	 Impacts • 2024 Increase in personnel costs, as a result of 	Other issues with an impact on the P&L 2024
Total income	Growth vs 2023 6-8%	 Double-digit growth in our Calcifediol and Mesalazine licenses 	the new labour agreement • Depreciation of the	• Increase in overheads due to the start-up of the industrial plant in Derio
EBITDA	Growth vs 2023 3-5%	 Mid-single-digit growth (above market) of the Medical Visit, Healthcare and Consumer businesses in Spain 	 Yen (impact on Bilastine Licensing business) Price reduction of Bilastine in Spain at the end of 2023. 	 Increased investments in R&D&I







DISCLAIMER

This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an offer of financing, nor an offer to sell or to buy Faes Farma shares.

The information included in this presentation has not been verified by independent sources and some of the information is presented in summarized form. No declaration or guarantee, explicit or implicit, are expressed by the Faes Farma Group, nor by its directors, managers, employees or representatives regarding the fairness, precision, completeness or accuracy of the information or opinions expressed in this document, and they should not serve as a reliable support. No member of the Faes Farma Group, nor its directors, managers, employees or representatives will assume any responsibility (due to negligence or any other reason) on account of any loss, damage, cost or prejudice, direct or consequential, that occurs as a result of the use of this presentation or its content or in any other way in relation to the presentation, except with respect to any liability for fraud,, whether direct or indirect, explicit or implicit, contractual, criminal, regulatory or otherwise nature, in relation to the accuracy or completeness of the information in relation to the opinions included in this document or any error, omission or inaccuracy included in this presentation.

Faes Farma does not guarantee the accuracy of the information contained in this presentation, nor that it is complete. The information contained herein has been obtained from sources considered trustworthy by Faes Farma, but Faes Farma does not represent or guarantee that it is complete or exact, in particular with regard to data provided by third parties.

This presentation contains information and affirmations or statements with future projections about the Faes Farma Group. Such statements include financial projections and estimates with their underlying assumptions that are not historical facts. In this sense, although the Faes Farma Group. considers that the expectations received in such statements are reasonable, warns that the information and statements with future projections are subject to risks and uncertainties, known or unknown, that could cause the evolution of the group's business to be different from that expressed or inferred and condition its materialization.